克拉霉素治疗实验性体内莱姆病的疗效。
Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo.
作者信息
Alder J, Mitten M, Jarvis K, Gupta P, Clement J
机构信息
Anti-Infective Research Division, Abbott Laboratories, Abbott Park, Illinois 60064-3500.
出版信息
Antimicrob Agents Chemother. 1993 Jun;37(6):1329-33. doi: 10.1128/AAC.37.6.1329.
Abstract
Clarithromycin provided effective therapy against arthritis induced by Borrelia burgdorferi infection in the hamster. In vitro, clarithromycin was at least 1 log more potent than tetracycline against two isolates of B. burgdorferi from human sources, as measured by MICs and 50% inhibitory concentrations. Clarithromycin was effective in preventing the onset of B. burgdorferi-induced arthritis, as determined by several parameters of paw swelling. When administered after the onset of arthritis, clarithromycin therapy reduced the degree of swelling and decreased recovery time. These results suggest that clarithromycin has potential as an effective therapy for Lyme disease.
摘要
克拉霉素对仓鼠因伯氏疏螺旋体感染诱发的关节炎提供了有效的治疗。在体外，通过最小抑菌浓度（MICs）和50%抑制浓度测定，克拉霉素对两株来自人类的伯氏疏螺旋体分离株的效力比四环素至少高1个对数级。通过爪肿胀的几个参数确定，克拉霉素在预防伯氏疏螺旋体诱发的关节炎发作方面有效。当在关节炎发作后给药时，克拉霉素治疗降低了肿胀程度并缩短了恢复时间。这些结果表明克拉霉素有作为莱姆病有效治疗方法的潜力。
相似文献
1
Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo.克拉霉素治疗实验性体内莱姆病的疗效。
Antimicrob Agents Chemother. 1993 Jun;37(6):1329-33. doi: 10.1128/AAC.37.6.1329.
2
Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents.莱姆病螺旋体伯氏疏螺旋体对头孢呋辛及其他抗菌药物的体外和体内敏感性比较
Antimicrob Agents Chemother. 1990 Nov;34(11):2133-6. doi: 10.1128/AAC.34.11.2133.
3
Experimental Borrelia burgdorferi infection of outbred mice.远交系小鼠的实验性伯氏疏螺旋体感染
J Clin Microbiol. 1992 Nov;30(11):3016-8. doi: 10.1128/jcm.30.11.3016-3018.1992.
4
[Comment on Borrelia burgdorferi Group infections].[关于伯氏疏螺旋体菌群感染的评论]
Orv Hetil. 2002 May 26;143(21):1223-4.
5
Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease.埃维霉素（SCH27899）在体外及莱姆病动物模型中的疗效。
Antimicrob Agents Chemother. 2001 Mar;45(3):936-7. doi: 10.1128/AAC.45.3.936-937.2001.
6
Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi.克拉霉素、阿奇霉素和红霉素对伯氏疏螺旋体的体外比较活性
Antimicrob Agents Chemother. 1993 Aug;37(8):1704-6. doi: 10.1128/AAC.37.8.1704.
7
[Suspected Lyme borreliosis: how to diagnose, whom to treat?].
Ther Umsch. 1992 Apr;49(4):257-62.
8
Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi.难治性慢性莱姆关节炎与HLA-DR4及对伯氏疏螺旋体OspA和OspB的抗体反应性的关联
Infect Immun. 1993 Jul;61(7):2774-9. doi: 10.1128/iai.61.7.2774-2779.1993.
9
In-vitro and in-vivo susceptibility of Borrelia burgdorferi to azithromycin.
J Antimicrob Chemother. 1990 Jan;25 Suppl A:33-8. doi: 10.1093/jac/25.suppl_a.33.
10
Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis.伯氏疏螺旋体的杀灭动力学及与莱姆病治疗相关的细菌学发现
Infection. 1996 Jan-Feb;24(1):9-16. doi: 10.1007/BF01780643.
引用本文的文献
1
The In Vitro Antimicrobial Susceptibility of sensu lato: Shedding Light on the Known Unknowns.广义的体外抗菌药敏性：揭示已知的未知因素。
Pathogens. 2023 Sep 28;12(10):1204. doi: 10.3390/pathogens12101204.
2
Clinical evidence of human pathogens implicated in Alzheimer's disease pathology and the therapeutic efficacy of antimicrobials: an overview.涉及阿尔茨海默病病理学的人类病原体的临床证据和抗菌药物的治疗效果：概述。
Transl Neurodegener. 2023 Jul 26;12(1):37. doi: 10.1186/s40035-023-00369-7.
3
Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.莱姆病的证据评估与指南建议：已知蜱虫叮咬、游走性红斑皮疹及持续性疾病的临床管理
Expert Rev Anti Infect Ther. 2014 Sep;12(9):1103-35. doi: 10.1586/14787210.2014.940900. Epub 2014 Jul 30.
4
Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know.伯氏疏螺旋体狭义种的抗菌药敏性：我们已知的、未知的以及需要了解的内容。
Wien Klin Wochenschr. 2006 Nov;118(21-22):659-68. doi: 10.1007/s00508-006-0693-z.
5
Choosing the right macrolide antibiotic. A guide to selection.选择合适的大环内酯类抗生素。选择指南。
Drugs. 1997 Mar;53(3):349-57. doi: 10.2165/00003495-199753030-00002.
6
Clarithromycin in treatment of early Lyme disease: a pilot study.克拉霉素治疗早期莱姆病：一项试点研究。
Antimicrob Agents Chemother. 1996 Feb;40(2):468-9. doi: 10.1128/AAC.40.2.468.
本文引用的文献
1
The early clinical manifestations of Lyme disease.莱姆病的早期临床表现。
Ann Intern Med. 1983 Jul;99(1):76-82. doi: 10.7326/0003-4819-99-1-76.
2
The spirochetal etiology of Lyme disease.莱姆病的螺旋体病因
N Engl J Med. 1983 Mar 31;308(13):733-40. doi: 10.1056/NEJM198303313081301.
3
Susceptibility of the Lyme disease spirochete to seven antimicrobial agents.莱姆病螺旋体对七种抗菌药物的敏感性。
Yale J Biol Med. 1984 Jul-Aug;57(4):549-53.
4
Isolation and cultivation of Lyme disease spirochetes.莱姆病螺旋体的分离与培养。
Yale J Biol Med. 1984 Jul-Aug;57(4):521-5.
5
In vitro and in vivo susceptibility of Borrelia burgdorferi.伯氏疏螺旋体的体外和体内药敏性
Eur J Clin Microbiol. 1987 Aug;6(4):424-6. doi: 10.1007/BF02013102.
6
Ceftriaxone as effective therapy in refractory Lyme disease.
J Infect Dis. 1987 Jun;155(6):1322-5. doi: 10.1093/infdis/155.6.1322.
7
In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents.莱姆病螺旋体伯氏疏螺旋体对四种抗菌药物的体外和体内敏感性
Antimicrob Agents Chemother. 1987 Feb;31(2):164-7. doi: 10.1128/AAC.31.2.164.
8
Lyme disease.莱姆病
Clin Rheum Dis. 1986 Aug;12(2):343-67.
9
Induction of lyme arthritis in LSH hamsters.在LSH仓鼠中诱导莱姆关节炎。
Infect Immun. 1988 Sep;56(9):2336-42. doi: 10.1128/iai.56.9.2336-2342.1988.
10
Specific immune responses in Lyme borreliosis. Characterization of T cell and B cell responses to Borrelia burgdorferi.
Ann N Y Acad Sci. 1988;539:93-102. doi: 10.1111/j.1749-6632.1988.tb31842.x.
Zotero 插件